Drug Trial Radar · NCT07939815
A Study of BMS-986548 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
171
Planned (sponsor's estimate)
Start
Nov 30, 2026
Primary completion
Dec 29, 2029
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Nov 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability, efficacy, and drug levels of BMS-986548 as a monotherapy and in combination with anti-cancer agents in participants with advanced solid malignancies.
Conditions
- Advanced Solid Malignancies
Interventions
BMS-986548Drug
Specified dose on specified days
CetuximabDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs)Time frame: Up to 30 days after last dose
- Number of participants with serious adverse events (SAEs)Time frame: Up to 30 days after last dose
- Number of participants with AEs meeting protocol defined Dose-Limiting Toxicity (DLT) criteriaTime frame: Up to 30 days after last dose
- Number of participants with AEs leading to discontinuationTime frame: Up to 30 days after last dose
- Number of deathsTime frame: Up to 30 days after last dose
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Local Institution - 0001
San Antonio, Texas
Local Institution - 0004
West Valley City, Utah
Local Institution - 0002
Vancouver, British Columbia, Canada
Local Institution - 0003
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.